Akèy › Kansè Metastatik › Pennsylvania › Pittsburgh
Etid klinik pou Kansè Metastatik nan Pittsburgh, PA
31 etid pou Kansè Metastatik ap chèche patisipan nan sit nan ak bò kote Pittsburgh (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Ap rekriteFaz 2
- UPMC-Magee Womens Hospital, Pittsburgh
- UPMC Hillman Cancer Center, Pittsburgh
- UPMC-Passavant Hospital, Pittsburgh
- ak 3 plis
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
Ap rekriteFaz 1
- UPMC Hillman Cancer Center, Pittsburgh
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ap rekriteFaz 1/2
- University of Pittsburgh Medical Center, Pittsburgh
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Ap rekriteFaz 2/3
- University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, Pittsburgh
Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
Ap rekriteFaz 1
- UPMC Hillman Cancer Center, Pittsburgh
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Ap rekriteFaz 1
- University of Pittsburgh Medical Center, Pittsburgh
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Ap rekriteFaz 3
- AHN Allegheny General Hospital, Pittsburgh
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Ap rekriteFaz 1/2
- Allegheny Health Network, Pittsburgh
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
Ap rekriteFaz 1/2
- UPMC Hillman Cancer Center ( Site 0014), Pittsburgh
CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Clinical Study Site, Pittsburgh
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Ap rekriteFaz 3
- UPMC Hillman Cancer Center, Pittsburgh
Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer
Ap rekriteFaz 1
- UPMC Hillman Cancer Center, Pittsburgh
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
Ap rekriteFaz 1
- UPMC Hillman Cancer Center, Pittsburgh
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Ap rekriteFaz 1
- Allegheny General Hospital, Pittsburgh
- University of Pittsburgh Medical Center, Pittsburgh
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
Ap rekriteFaz 1
- UPMC Hillman Cancer Center, Pittsburgh
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
Ap rekriteFaz 1/2
- UPMC Hillman Cancer Center, Pittsburgh
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
Ap rekriteFaz 3
- Research Site, Pittsburgh
- Research Site, Pittsburgh
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- University of Pittsburg Medical Center _UPMC Hillman Cancer Center, Pittsburgh
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Ap rekriteFaz 3
- AHN Cancer Center, Pittsburgh
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Ap rekriteFaz 1
- University of Pittsburg Medical Center (UPCM), Pittsburgh
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
Ap rekriteFaz 2/3
- University of Pittsburgh Medical Center(UPMC)-Hillman Cancer Center, Pittsburgh
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
Ap rekriteFaz 1/2
- University of Pittsburgh Medical Center - Hillman Cancer Center, Pittsburgh
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
Ap rekriteFaz 2/3
- UPMC Hillman Cancer Center, Pittsburgh
Window of Opportunity in Preserving Laryngeal Function Trial
Ap rekriteFaz 2
- UPMC Hillman Cancer, Pittsburgh
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
Ap rekriteFaz 3
- University of Pittsburgh Medical Center - Hillman Cancer Center, Pittsburgh
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Ap rekriteFaz 2/3
- UPMC Hillman Cancer Center, Pittsburgh
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
Ap rekriteFaz 1
- Hillman Cancer Center, Pittsburgh
Heated Versus Aerosol-based Laparoscopic Chemotherapy for Cancer That Has Spread to the Peritoneum (Abdominal Lining)
Ap rekriteFaz 2
- Allegheny Health Network West Penn Hospital, Pittsburgh
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
Ap rekriteFaz 3
- University of Pittsburgh Medical Center-Hillman Cancer Center, Pittsburgh
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
Ap rekriteFaz 1/2
- University of Pittsburgh, Pittsburgh
Etid Kansè Metastatik nan lòt vil
- Houston, TX104 etid
- New York City, NY93 etid
- Nashville, TN70 etid
- Boston, MA63 etid
- Los Angeles, CA57 etid
- St. Louis, MO54 etid
- Arlington, VA53 etid
- Philadelphia, PA46 etid
- Chicago, IL45 etid
- San Antonio, TX44 etid
- Washington, DC43 etid
- Dallas, TX42 etid
Lòt etid nan Pittsburgh
- Kansè Poumon ki pa ti selil48 etid
- Kansè (tout kalite)41 etid
- Kansè nan tete39 etid
- Kansè kolorektal32 etid
- Melanom31 etid
- Kansè ovè30 etid
- Kansè Endomèt23 etid
- Kansè pwostat23 etid
- Kansè poumon23 etid
- Karsinòm selil skuamèz tèt ak kou22 etid
- Akidan serebavaskilè22 etid
- Depresyon22 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.